Entrada Therapeutics (TRDA)
(Delayed Data from NSDQ)
$16.78 USD
+0.97 (6.14%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$16.78 USD
+0.97 (6.14%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $16.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth A Momentum C VGM
Zacks News
AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer
by Zacks Equity Research
AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up
by Zacks Equity Research
Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.
Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath
by Zacks Equity Research
The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
by Zacks Equity Research
A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination
by Zacks Equity Research
Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.
FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow
by Zacks Equity Research
FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.
Here's Why You Should Invest in BioMarin (BMRN) Stock Now
by Zacks Equity Research
Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.
Exelixis (EXEL) Gains 14.9% in a Week on Strong Q2 Results
by Zacks Equity Research
Exelixis' (EXEL) shares rally following an impressive performance in the second quarter, buoyed by a surge in license revenues.
Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 138.46% and 72.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion's (ESPR) Q2 Loss Narrows, Revenues Soar Year Over Year
by Zacks Equity Research
Esperion (ESPR) reports a narrower-than-expected loss for the second quarter of 2024. Revenues beat estimates. Sales rise year over year owing to higher collaboration revenues.
Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B
by Zacks Equity Research
Merck (MRK) to acquire worldwide rights to a novel investigational clinical-stage bispecific antibody for treating B-cell-associated diseases. The deal is expected to close by third-quarter 2024.
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
by Zacks Equity Research
Pacira (PCRX) falls 48% as the District Court of New Jersey rules that the company's '495 patent for its lead drug, Exparel, is not valid.
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Avidity Biosciences (RNA) delivered earnings and revenue surprises of 14.47% and 71.16%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View
by Zacks Equity Research
Insmed (INSM) posts mixed second-quarter results. It reaches alignment with the FDA on the primary endpoint of a late-stage study that seeks to expand the label of Arikayce.
Intellia's (NTLA) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Intellia's (NTLA) second-quarter 2024 earnings and revenues lag estimates. The company provides developmental and regulatory updates on its pipeline candidates.
Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook
by Zacks Equity Research
Novavax (NVAX) posts dismal second-quarter results. It also slashes its total revenue guidance, citing lower COVID-19 vaccine uptake.
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Cytokinetics (CYTK) Q2 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Cytokinetics (CYTK) reports wider-than-expected Q2 loss as operating expenses increase. CYTK is on track to complete the rolling NDA submission for aficamten in the third quarter.
Gilead (GILD) Q2 Earnings Beat, Annual Profit Guidance Raised
by Zacks Equity Research
Gilead (GILD) Q2 earnings and sales beat estimates on high HIV, oncology and liver disease drug sales and low expenses.
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
by Zacks Equity Research
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
SpringWorks (SWTX) Q2 Earnings Beat, Ogsiveo Drives Revenues
by Zacks Equity Research
SpringWorks (SWTX) reports better-than-expected second-quarter results. The newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.
Kymera (KYMR) Q2 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kymera (KYMR) reports a narrower-than-expected loss in the second quarter. The company expects the current cash balance to provide a runway into the first half of 2027.
Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss
by Zacks Equity Research
Viatris' (VTRS) earnings beat estimates in the second quarter but sales miss the same. New products are performing well and the rise in annual guidance for these products' sales is encouraging.
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.